Events, news, and information for the people who influence the business strategies of the life science industry.

Exicure’s CEO describes unique SNA™ technology now in clinical trials

Share this article

Dr. David Giljohann, CEO of Exicure, outlines the company’s unique spherical nucleic acid (SNA™) technology and how this three-dimensional arrangement of nucleic acid will solve the delivery challenge to get into cells and tissues. The biotech company is using digital drug design to use DNA and RNA sequences to create medicines that go after the underlying causes of genetic disease. Exicure’s lead programs address inflammatory diseases, genetic disorders and oncology.'


Share this article

Upcoming event

BIO-Europe Spring

23 - 25 Mar 2020, Paris, France
Connect with the right partners at Europe’s largest springtime biotech partnering event
Go to site